Wavefront-guided LASIK for myopia using the LADAR CustomCornea and the VISX CustomVue

PURPOSE: To evaluate the objective and subjective visual outcomes and refractive results of wavefront-guided LASIK with LADAR CustomCornea and VISX CustomVue. METHODS: This prospective randomized single-institution multisurgeon study comprised 100 eyes of 58 patients (50 eyes on each laser platform). Uncorrected visual acuity (UCVA), best spectacle corrected visual acuity (BSCVA), and manifest refraction were measured postoperatively at 1 day, 1 week, 1 month, and 3 months. Contrast sensitivity, higher order aberrations measurement, and a subjective vision questionnaire were performed preoperativey and at 3 months. RESULTS: Preoperatively, the CustomCornea group had a mean manifest sphere of -3.58±1.61 diopters (D) (range: -0.50 to -7.25 D), cylinder of +0.64±0.45 D (range: 0 to +1.75 D), and manifest refractive spherical equivalent (MRSE) of -3.26±1.56 D. The CustomVue group had a manifest sphere of -4.00±1.69 D (range: -1.50 to - 7.50 D), cylinder of +0.60±0.52 D (range: 0 to +2.00 D), and MRSE of -3.70±1.64 D. At 3 months, 94% of CustomCornea eyes and 84% of CustomVue eyes had UCVA ≥20/20 (P=.20). Twenty-four percent of CustomVue eyes and 22% of Custom-Cornea eyes gained 1 line of BSCVA. In both groups, 96% of eyes were within 0.50 D of emmetropia. Mean CustomCornea glare contrast sensitivity improved (P=.04) whereas more eyes improved than worsened in both groups. Spherical aberration and total higher order aberrations increased, and trefoil decreased in both groups. A decrease in coma was noted in 70% of CustamCornea eyes. CONCLUSIONS: Wavefront-guided LASIK with both platforms is safe, effective, and delivers excellent visual results. CustomCornea improves contrast sensitivity under glare conditions.